rewrite this title AbbVie ovarian cancer drug shows 62.7% response rate in trial By Investing.com

NORTH CHICAGO, Ill. – AbbVie (NYSE:ABBV) presented Phase 2 trial results for mirvetuximab soravtansine-gynx combined with carboplatin in patients with platinum-sensitive ovarian cancer at the Society of Gynecologic Oncology Annual Meeting today.The $367.8 billion biotechnology giant, which generated $61.16 billion in revenue over the last twelve months, continues expanding its oncology pipeline. According to InvestingPro analysis, the stock currently appears on the most overvalued list based on Fair Value metrics. Investors can access a comprehensive Pro Research Report on ABBV, one of 1,400+ available reports that transform complex data into actionable intelligence.

The IMGN853-0420 trial enrolled 125 patients with folate receptor alpha-positive, recurrent platinum-sensitive ovarian cancer who had received one prior platinum-based chemotherapy regimen. Participants received mirvetuximab soravtansine-gynx plus carboplatin every three weeks for six to eight cycles, followed by single-agent mirvetuximab soravtansine-gynx as continuation therapy.

The primary endpoint showed a confirmed objective response rate of 62.7% in patients with at least 50% folate receptor alpha expression after six cycles of combination therapy, according to a press release statement. The overall population with at least 25% expression showed a 62.4% response rate. Median duration of response was 11.2 months across the overall population.

Among patients who transitioned to monotherapy continuation, the response rate reached 68% across the overall population. Nearly half of trial participants had prior exposure to PARP inhibitors, a group that may experience reduced responses to subsequent platinum-based chemotherapy. In this subgroup, the response rate was 63.9%.

The safety profile was consistent with previous studies. The most common treatment-related adverse events were low-grade ocular events, including corneal changes that were reversible in over 90% of patients. The most common grade 3 or higher treatment-related adverse events included neutropenia at 15%, blurred vision at 10%, and thrombocytopenia at 10%.

The combination regimen is not approved in the U.S., E.U., or any other territory. Mirvetuximab soravtansine-gynx is currently approved as a monotherapy for folate receptor alpha-positive, platinum-resistant ovarian cancer in patients who have received one to three prior systemic treatment regimens.

In other recent news, AbbVie Inc. reported a projected $744 million in acquired in-process research and development expenses for the first quarter of 2026. This expense is expected to negatively impact the company’s earnings per share by $0.41. The final results for the quarter are yet to be finalized and may differ from these preliminary estimates. Meanwhile, RBC Capital reiterated its Outperform rating on AbbVie with a $260 price target, anticipating an in-line quarter for the first quarter of 2026. Guggenheim also adjusted its price target, raising it to $249 while maintaining a Buy rating, based on discussions with AbbVie’s investor relations team. Conversely, Cantor Fitzgerald lowered its price target for AbbVie to $240, maintaining an Overweight rating but expecting Skyrizi and Rinvoq to outperform company guidance. Additionally, Allergan Aesthetics, a division of AbbVie, presented promising data on a new investigational botulinum neurotoxin at a dermatology meeting. The neurotoxin, TrenibotulinumtoxinE, showed positive results in reducing glabellar line severity in a Phase 3 study.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.